Your browser doesn't support javascript.
loading
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
Shinkai, Masaharu; Sonoyama, Takuhiro; Kamitani, Akari; Shibata, Risa Yokokawa; Seki, Naomi M; Omoto, Shinya; Shinoda, Masahiro; Sato, Takashi; Ishii, Naoki; Igarashi, Kenji; Ariyasu, Mari.
  • Shinkai M; Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan.
  • Sonoyama T; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
  • Kamitani A; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
  • Shibata RY; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
  • Seki NM; Shionogi & Co., Ltd., Pharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Omoto S; Shionogi & Co., Ltd., Pharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Shinoda M; Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan.
  • Sato T; Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan.
  • Ishii N; Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan.
  • Igarashi K; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.
  • Ariyasu M; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan. Electronic address: mari.tatsuno@shionogi.co.jp.
Vaccine ; 40(32): 4328-4333, 2022 07 30.
Article en En | MEDLINE | ID: mdl-35738968
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 / Vacuna BNT162 Tipo de estudio: Clinical_trials Límite: Adult / Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 / Vacuna BNT162 Tipo de estudio: Clinical_trials Límite: Adult / Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article